Hengrui Medicine announces share repurchase progress

Jiangsu Hengrui Medicine (SSE:600276) announced the progress of its share repurchase plan, initially disclosed on May 16, 2024. As of April 30, 2025, the company has cumulatively repurchased 8,584,144 shares, representing 0.13% of the company's total share capital. The repurchases were executed through centralized bidding transactions, with prices ranging from CNY 39.00 to CNY 57.01 per share. The total expenditure for the repurchase program to date is CNY 376,251,147.80 (excluding transaction costs). The company stated that the repurchase activities align with relevant laws and regulations and the company's established repurchase plan, which is intended for employee stock ownership or equity incentives. The repurchase program, approved by the board on May 15, 2024, aims to repurchase shares for a total amount between CNY 600 million and CNY 1.2 billion, with a maximum repurchase price of CNY 67.38 per share and will continue until May 2025.